High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. - Wikidata - awgldk - TriplyDB

High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group.

High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group.

http://www.wikidata.org/entity/Q37615003

about

Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma: A Retrospective Study of 164 Cases.Advances in emerging drugs for osteosarcoma.An update on chemotherapy for osteosarcoma.

P2860

Q35857892-E953C475-D682-40B5-AFEB-E9ED77F7B957 Q38506118-7F2B5B8A-B95F-4010-A288-1114C8BD029E Q38619114-EF19AE20-C416-4680-9F0C-A584BBCBBECC

P2860

High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group.

http://www.wikidata.org/entity/Q37615003

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

High Dose Thiotepa in Patients ...... Experience of the SFCE Group.

@en

High Dose Thiotepa in Patients ...... Experience of the SFCE Group.

@nl

type

label

High Dose Thiotepa in Patients ...... Experience of the SFCE Group.

@en

High Dose Thiotepa in Patients ...... Experience of the SFCE Group.

@nl

prefLabel

High Dose Thiotepa in Patients ...... Experience of the SFCE Group.

@en

High Dose Thiotepa in Patients ...... Experience of the SFCE Group.

@nl

P1433

Q37615003-1598558D-2F4E-4B30-B070-842CDBCC6592

P1476

Q37615003-C87EF788-1A0D-4878-B5C3-716D7A8B2310

P2093

Q37615003-42B0AA4D-4E6A-4117-9471-6A96BE0F7616

Q37615003-4B27C4C9-60D5-4679-AA20-1046146E73B2

Q37615003-4FDCC23E-60B9-4A58-B4F8-6149AC9AE8B1

Q37615003-64181FEB-F208-4D9F-B7CA-A365D74C283C

Q37615003-6478D79F-06E9-4545-8649-E83BBF089531

Q37615003-694A40FC-C627-48F9-9369-0D30891CE76E

Q37615003-81A93D23-7C7E-414F-BB84-7D765CC1F67A

Q37615003-C637F822-E3EF-4A7F-8CBD-76497B543377

Q37615003-DD332CEC-48C3-4393-A22A-7FFA65C9CA04

P2860

Q37615003-02119378-A6E2-41F7-A325-3EBC81197DA7

Q37615003-08DB008F-9278-4527-A047-E363B0A80335

Q37615003-1FB614D0-7DCE-4026-9FFB-CCE51C8CB4E2

Q37615003-26A4BC87-4F31-4888-B46A-65F5EDB7C009

Q37615003-3648DDFF-E3C7-4F53-A4F9-CC29FC1032C1

Q37615003-396BA0E9-80CE-41E2-8766-ED8703404A64

Q37615003-42C3F670-1269-4207-A26D-DE8A3BE683AE

Q37615003-5D6B9627-677C-4F7D-AEED-9E1234CD3B10

Q37615003-6C4E0CDE-E708-4291-9CF4-2BFDB490EE60

Q37615003-76041FCC-92AA-49B2-AEF9-801DE91D0130

P304

Q37615003-E5DEFB66-3108-44B0-92FF-444B62EF380B

P31

Q37615003-44EE7D93-6B81-4AE0-BAA0-05177D41A152

P356

Q37615003-344EC623-DB65-4F1C-ACF3-25FFF3B19649

P478

Q37615003-4E7542FF-A7F6-49AA-908F-942D37AACA54

P50

Q37615003-3BBC0727-B0C1-40CE-A8E1-C5AFB5AFFEAD

P577

Q37615003-CB599AF9-0236-4AEE-9CC9-4D26D7EC4760

P5875

Q37615003-1D8B6A10-1BF1-41A7-92D3-81470B6FA8A6

P698

Q37615003-F1ABF42E-8CAA-48FE-A53E-C4C645C5C8D7

P932

Q37615003-21C295FB-A9A0-4B0C-B5F2-5C227FB1C275

P356

P1433

P1476

High Dose Thiotepa in Patients ...... Experience of the SFCE Group.

@en

P2093

Claudine Schmitt

http://www.w3.org/2001/XMLSchema#string

Cyril Lervat

http://www.w3.org/2001/XMLSchema#string

Céline Segura-Ferlay

http://www.w3.org/2001/XMLSchema#string

Helene Pacquement

http://www.w3.org/2001/XMLSchema#string

Jean-Claude Gentet

http://www.w3.org/2001/XMLSchema#string

Laurence Brugières

http://www.w3.org/2001/XMLSchema#string

Marie-Dominique Tabone

http://www.w3.org/2001/XMLSchema#string

Nathalie Gaspar

http://www.w3.org/2001/XMLSchema#string

Perrine Marec-Berard

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Nonparametric Estimation from Incomplete Observations

A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study.

Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.

Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors.

High-dose chemotherapy for solid tumors: results of the EBMT.

High-dose therapy with autologous stem cell rescue for pediatric sarcomas.

Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.

High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies.

A meta-analysis of osteosarcoma outcomes in the modern medical era

P304

475067

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/475067

http://www.w3.org/2001/XMLSchema#string

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

Perrine Marec-Bérard

P577

2014-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261140476

http://www.w3.org/2001/XMLSchema#string

P698

24672280

http://www.w3.org/2001/XMLSchema#string

P932

3941142

http://www.w3.org/2001/XMLSchema#string